Le Lézard
Classified in: Health
Subject: PET

Explosive Growth Projected in US Pet Medication Market, the Industry to Reach $17.90 Billion by 2029 - Exclusive Focus Insight Report by Arizton


CHICAGO, April 2, 2024 /PRNewswire/ -- According to Arizton's latest focus research report, the US pet medication market is growing at a CAGR of 5.20% during 2023-2029. 

US Pet Medication Market Focus Research Report by Arizton


To Know More, Download the Free Sample Report:
https://www.focusreports.store/report/us-pet-medication-market-focused-insights

The U.S. Pet Medication Market?Report Scope???

Report Attributes????? 

Details?????? 

Market Size (2029)????? 

USD 17.90 Billion?? 

Market Size (2023)????? 

USD 13.21 Billion?? 

CAGR (2023-2029)????? 

5.20 %

Historic Year???? 

2020-2022

Base Year???? 

2023

Forecast Year????? 

2024-2029????? 

The US pet medication market is projected to increase, driven by the pet humanization trend and the ensuing commercialization of a broad range of pet care products coupled with the growing focus on safe food and a parallel emphasis shed on raising healthy livestock. The rising throwaway income of pet owners pertains to the middle-income group, and the growing trend of nuclear families is the major key factor for the growth of the pet care market in the coming years. The increase in the adoption of pets and the high demand for pet products are the major factors driving the US pet medication market.

The growth of the pet medication market is also influenced by a heightened level of awareness and education regarding the benefits of pet medication. Veterinary and pet organizations have been proactive in creating awareness campaigns and educational initiatives to inform pet owners about the advantages of having medication & insurance coverage for their pets. These efforts have successfully dispelled misconceptions and myths surrounding pet insurance, improving pet owners' understanding. As a result, more individuals realize that pet medication protects their pets' health and provides peace of mind by ensuring that the insurance providers cover unexpected medical expenses. The ongoing efforts to educate the public about the value of pet insurance contribute significantly to the market growth, as informed pet owners are more likely to invest in policies that safeguard their pets' well-being while offering financial security. Several major players focus on strategic acquisitions, licensing, and collaboration agreements with emerging players to enter the US pet medication market and access commercially launched products. For instance, in 2023, Elanco Animal Health Incorporated announced that the US Food and Drug Administration (FDA) approved Varenzin-CA1 (molidustat oral suspension) as the first and only treatment to control non-regenerative anaemia in cats with chronic kidney disease (CKD). 

Over-the-Counter Medications the Fastest Growing Segment in the US Pet Medication Market

The over-the-counter (OTC) medications segment is poised to reach a substantial revenue of $8.51 billion by the conclusion of the forecasting period, marking it as the fastest-growing sector with an impressive absolute growth rate of 39.19% and an incremental growth of $2.40 billion throughout the forecast duration. This surge is primarily propelled by a heightened awareness among pet owners regarding the significance of pet healthcare, prompting them to seek accessible and effective healthcare solutions for their cherished companions.

A discernible trend has emerged in favor of herbal topical medications for addressing common pet ailments such as fleas and allergies. This shift towards herbal and natural remedies resonates with a broader consumer inclination towards organic and sustainable products. Natural OTC medications, often incorporating natural ingredients, appeal to pet owners seeking safer and gentler alternatives for their pets, aligning seamlessly with the prevailing consumer preference for natural and organic products and further fueling the demand for natural pet OTC medications.

The flea and tick control segment represents the largest share of the OTC pet medication market, driven by the increasing incidences of parasitic infections in pets during the forecast period. Moreover, the convenience and accessibility offered by online retailers serve as a significant catalyst for pet owners, facilitating the purchase of OTC pet medications through e-commerce platforms, which saves time and effort compared to traditional physical stores. Additionally, consumers can procure OTC pet medications, predominantly flea and tick control products, from veterinarians or retail outlets without needing a prescription.

About the Report:

The study considers a detailed scenario of the present U.S. pet medication market and its market dynamics for 2024?2029 in the U.S. It covers a thorough overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.

Get this Report for Lesser with Our Subscription Services: https://www.focusreports.store/report/us-pet-medication-market-focused-insights

Segmentation & Forecast

Vendors List

Table of Contents

CHAPTER ? 1: Pet Medication Market Overview

CHAPTER ? 2: Pet Medication Market

CHAPTER ? 3: Pet Medication Market Segmentation Data

CHAPTER ? 4: Pet Medication Market Prospects & Opportunities

CHAPTER ? 5: Pet Medication Industry Overview

CHAPTER ? 6: Appendix

Check Out Some of the Top Selling Research Reports: 

U.S. Dermocosmetics Market - Focused Insights 2023-2028
U.S. Dental Cement Market - Focused Insights 2023-2028

U.S. Retail Bags Market - Focused Insights 2024-2029

U.S. Assisted Living Facilities Market - Focused Insights 2023-2028

About Focused Reports by Arizton?????????? 

Welcome to Focused Reports, an esteemed Arizton Advisory & Intelligence subsidiary committed to delivering precise and insightful market research reports across all key geographies. Our unique selling proposition lies in our affordable pricing, accurate data, in-depth research, and presentation-ready reports. With us, expensive market research is a thing of the past. We aim to be strategic, providing valuable data. Focus Reports is where folks come to name their ideas, create a compelling brand and a great-looking website, and attract customers with digital and social marketing.????????? 

About Us:????????????????????????????????????????????????????? 

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.???????????????????????????????????????????????????????? 

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.????????????????????????????????????????????????????????? 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.?????????? 

Contact Us:?????????? 

Call: +1-312-235-2040????????????????????????????????????????????????????? 
????????? +1 302 469 0707???????????????????????????????????????????????????? 
Mail: [email protected]????????? 

Website: https://www.focusreports.store/????? 

Photo: https://mma.prnewswire.com/media/2377296/US_PET_MEDICATION_MARKET.jpg
Logo: https://mma.prnewswire.com/media/2326840/Focus_Reports_Logo.jpg

Focus Reports Logo

 


These press releases may also interest you

at 04:32
According to the latest BCC...

at 03:05
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

at 02:20
Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim...

2 mai 2024
The report titled "Muscle Stimulator Market by Technique (Burst Mode Alternating Current, Functional Electrical Stimulation, Interferential), Modality (Handheld, Portable, Table Top), Area, Application, End-User - Global Forecast 2024-2030" is now...

2 mai 2024
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have...



News published on and distributed by: